Prostate cancer
Conditions
Interventions
case series:abiraterone
Sponsors
Renji Hospital affiliated to Shanghai Jiaotong University, School of Medicine
Eligibility
Sex/Gender
Male
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: a) The age was 18-75 years old, male; b) Prostate adenocarcinoma was diagnosed by histopathology or cytology; c) According to eau-estro-siog 2016 guidelines, the clinical diagnosis was metastatic castration resistant prostate cancer; d) Had not received novel hormonal therapy such as abiraterone and enzalutamide; e) Had not received docetaxel or carbataxel or combination chemotherapy including docetaxel or carbataxel in the past; f) No previous treatment with PARP inhibitors; g) Had never received xofigo (radium 223 dichloride) treatment before; h) ECOG score was 0-2; i) The patients had normal organ function, WBC >= 3000 / mm3 or neutrophil count >= 1500 / mm3, AST and ALT were lower than 1.5 ULN; j) The survival time of the patients was expected to be more than 3 months; k) Patients sign informed consent and have the ability to follow the planned study visit, provide blood samples before and after treatment, provide clinical information and cooperate with other research steps.
Exclusion criteria
Exclusion criteria: a) Histopathological examination showed neuroendocrine / small cell prostate cancer; b) Hypertension and poor drug control; c) Patients with severe cardiopulmonary insufficiency; d) Abnormal coagulation function, bleeding tendency, or receiving thrombolytic or anticoagulant therapy; e) Any other malignant tumor previously diagnosed; f) There were other malignant tumors at the same time; g) Have a history of human immunodeficiency virus infection, or other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation, or have a history of organ transplantation; h) Unable to obtain clinical information needed for the study (e.g. loss of follow-up).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;PSA; | — |
Countries
China
Contacts
Public ContactDong Baijun
Renji Hospital affiliated to Shanghai Jiaotong University, School of Medicine
Outcome results
None listed